Treating Chronic Pain
Relieve Pain with the Fisher Wallace Stimulator®
The Fisher Wallace Stimulator® is a portable medical device that has been clinically proven and cleared by the FDA for the symptomatic relief of pain. The device works by using a gentle electrical current at patented frequencies to block pain and stimulate the production of beta-endorphins. The device may be used to treat post-operative back pain, arthritic pain, neuropathic pain, fibromyalgia, gastro-intestinal pain, headaches, gout, phantom limb syndrome and other forms of chronic and acute pain. (See our homepage for other FDA-Cleared applications, such as the treatment of depression, anxiety and insomnia). You may return your device for a refund within 60 days of receipt if it does not successfully treat your symptoms. Additionally, most insurance companies reimburse patients for the purchase of this device when it is prescribed for pain.
Many private insurance companies, such as Aetna, Cigna and Blue Cross will either pay for or reimburse the purchase of a Fisher Wallace Stimulator® when it is prescribed for the treatment of pain.
Use the reimbursement code E0720. Please call us with any questions.
How to Use the Device
Please refer to the Chronic Pain Treatment Instruction Manual for specifics of use.
For the treatment of depression, anxiety and insomnia, please see our homepage.
The Fisher Wallace Stimulator® may interfere with demand or sensing type cardiac pacemakers when used on the body.
Our device is designed to use at home, twice a day (morning and evening), for 20 minutes per treatment session. Symptoms typically begins to recede after 2 weeks of twice daily use - however, it may take 30-45 days to experience results. It is important to use the device every day. If you do not see any results after 45 days of twice-daily use, your symptoms will probably not recede as a result of using the device and you may return it for a refund.
The device may be safely used in conjunction with medication. Do not stop or reduce your medication without consulting your doctor.
A Selection of Published Research
J Rehabil Med. 2009 Mar;41(4):256-61.
Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial.
Weinberg Child Development Center, Safra Children''s Hospital at Sheba Medical Center, Affiliated to the Tel-Aviv University Sackler School of Medicine, Tel Hashomer, Israel. firstname.lastname@example.org
RESEARCH OBJECTIVE: To examine the efficacy of transcranial electrical stimulation a non-invasive method of reducing pain. DESIGN: A randomized, double-blind, placebo-controlled trial. SUBJECTS: A total of 119 patients with chronic pain. METHODS: Patients were treated with either transcranial electrical stimulation or an active placebo device. Short- and long-term follow-ups were evaluated for treatment efficacy with 4 ordinal scale variables: visual analogue scale (pain level), SLEEP (how often does pain disturb sleep), FREQ (frequency of pain) and MED (frequency of use of medications to relieve pain). RESULTS: Pain level decreased significantly in the transcranial electrical stimulation-treated group compared with the active-placebo group 3 weeks after the end of treatment (p = 0.0017 between groups). Other parameters did not demonstrate significant differences. Three months after the end of treatment this effect was maintained and other treatment parameters showed similar improvements. CONCLUSION: Transcranial electrical stimulation is an effective non-invasive method for pain relief. The active placebo device has a powerful effect on reported pain, which diminishes in the long-term. The involvement of possible neural mechanisms is discussed.
J Clin Rheumatol. 2001 Apr;7(2):72-8; discussion 78.
The treatment of fibromyalgia with cranial electrotherapy stimulation.
Robert Wood Johnson Medical School, East Brunswick, NJ 07719, USA.
In cranial electrotherapy stimulation (CES), micro-current levels of electrical stimulation are passed across the head via electrodes clipped to the ear lobes. After successful clinical use of CES with fibromyalgia patients in our clinic, it was decided to test these results with a double-blind, placebo-controlled study in which 60 randomly assigned patients were given 3 weeks of 1-hour-daily CES treatments, sham CES treatments, or were held as wait-in-line controls for any placebo effect in the sham-treated patients. Treated patients showed a 28% improvement in tender point scores, and a 27% improvement in self-rated scores of general pain level. The number of subjects rating their quality of sleep as poor dropped from 60% at the beginning of the study to 5%. In addition, there were significant gains in the self-rated feelings of well-being and quality of life, plus gains in six stress-related psychological test measures. No placebo effect was found among the sham-treated controls. A theoretical role of CES in affecting the brain''s pain message mechanisms and/or neurohormonal control systems is discussed. It is concluded that CES is as effective as the drug therapies in several trials, with no negative side effects, and deserves further consideration as an additional agent for the treatment of fibromyalgia.
Expert Rev Med Devices. 2007 Jul;4(4):489-95.
Cranial electrotherapy stimulation and fibromyalgia.
Gilula MF. President and Director, Life Energies Research Institute, 2510 Inagua Avenue, Miami, FL 33133, USA. email@example.com
Cranial electrotherapy stimulation (CES) is a well-documented neuroelectrical modality that has been proven effective in some good studies of fibromyalgia (FM) patients. CES is no panacea but, for some FM patients, the modality can be valuable. This article discusses aspects of both CES and FM and how they relate to the individual with the condition. FM frequently has many comorbidities such as anxiety, depression, insomnia and a great variety of different rheumatologic and neurological symptoms that often resemble multiple sclerosis, dysautonomias, chronic fatigue syndrome and others. However, despite long-standing criteria from the American College of Rheumatology for FM, some physicians believe there is probably no single homogeneous condition that can be labeled as FM. Whether it is a disease, a syndrome or something else, sufferers feel like they are living one disaster after another. Active self-involvement in care usually enhances the therapeutic results of various treatments and also improves the patient''s sense of being in control of the condition. D-ribose supplementation may prove to significantly enhance energy, sleep, mental clarity, pain control and well-being in FM patients. A form of evoked potential biofeedback, the EPFX, is a powerful stress reduction technique which assesses the chief stressors and risk factors for illness that can impede the FM patient''s built-in healing abilities. Future healthcare will likely expand the diagnostic criteria of FM and/or illuminate a group of related conditions and the ways in which the conditions relate to each other. Future medicine for FM and related conditions may increasingly involve multimodality treatment that features CES as one significant part of the therapeutic regimen. Future medicine may also include CES as an invaluable, cost-effective add-on to many facets of clinical pharmacology and medical therapeutics.
The Journal of Alternative and Complementary Medicine. 2003 Volume 9, p. 619 - 623.
Transcutaneous Electrical Nerve Stimulation: The Treatment of Choice for Pain and Depression
Shealy, Norman C, MD, PhD
Holos University Graduate Seminary, Fair Grove, MO
Information for your Doctor